IMNN · Imunon Inc. Common Stock
View on chartInsiders & Stakes
| Lindborg Stacy President and CEO | ▲ Buy | Grant | 113,197 Shares held | 9/25/2026 | View profile |
| Tardugno Michael H Executive Chairman of Board | ▲ Buy | Grant | 103,921 Shares held | 9/25/2026 | View profile |
| Goff Corinne Le President and CEO | ▲ Buy | Grant | 53,000 Shares held | 7/18/2022 | View profile |
| Faller Douglas Vincent Chief Medical Officer | ▲ Buy | Grant | 45,678 Shares held | 9/25/2026 | View profile |
| James E. Dentzer Director | ▲ Buy | Grant | 21,897 Shares held | 7/31/2026 | View profile |
| Fritz Frederick J. Director | ▲ Buy | Grant | 21,031 Shares held | 7/31/2026 | View profile |
| Hazard Sebastien Chief Medical Officer | ▲ Buy | Grant | 20,000 Shares held | 12/7/2023 | View profile |
| Braun Donald P Director | ▲ Buy | Grant | 15,499 Shares held | 7/31/2026 | View profile |
| Pellizzari Christine A Director | ▲ Buy | Grant | 15,076 Shares held | 7/31/2026 | View profile |
| Kardaras Constantine John Chief Accounting Officer | ▲ Buy | Grant | 10,000 Shares held | 12/14/2021 | View profile |
| Eylward Susan General Counsel and Corp Sec | ▼ Sell | Open Market | 2,896 Shares held | 8/31/2026 | View profile |
Transaction History
| Tardugno Michael H | ▲ Buy | Grant | 7,169 | $10K | 9/25/2026 |
| Lindborg Stacy | ▲ Buy | Grant | 6,697 | $9K | 9/25/2026 |
| Faller Douglas Vincent | ▲ Buy | Grant | 4,390 | $6K | 9/25/2026 |
| Tardugno Michael H | ▲ Buy | Grant | 5,824 | $9K | 9/11/2026 |
| Lindborg Stacy | ▲ Buy | Grant | 5,504 | $8K | 9/11/2026 |
| Faller Douglas Vincent | ▲ Buy | Grant | 4,211 | $6K | 9/11/2026 |
| Eylward Susan | ▼ Sell | Open Market | 2,525 | $4K | 8/31/2026 |
| Tardugno Michael H | ▲ Buy | Grant | 7,371 | $12K | 8/28/2026 |
| Lindborg Stacy | ▲ Buy | Grant | 6,822 | $11K | 8/28/2026 |
| Faller Douglas Vincent | ▲ Buy | Grant | 3,626 | $6K | 8/28/2026 |
| Eylward Susan | ▲ Buy | Grant | 2,525 | $4K | 8/28/2026 |
| Eylward Susan | ▼ Sell | Open Market | 2,449 | $4K | 8/17/2026 |
| Eylward Susan | ▲ Buy | Grant | 2,449 | $4K | 8/14/2026 |
| Tardugno Michael H | ▲ Buy | Grant | 7,147 | $12K | 8/14/2026 |
| Faller Douglas Vincent | ▲ Buy | Grant | 3,516 | $6K | 8/14/2026 |
| Lindborg Stacy | ▲ Buy | Grant | 6,615 | $11K | 8/14/2026 |
| Eylward Susan | ▼ Sell | Open Market | 2,541 | $4K | 8/3/2026 |
| Pellizzari Christine A | ▲ Buy | Grant | 6,934 | $11K | 7/31/2026 |
| James E. Dentzer | ▲ Buy | Grant | 6,934 | $11K | 7/31/2026 |
| Fritz Frederick J. | ▲ Buy | Grant | 6,934 | $11K | 7/31/2026 |
| Braun Donald P | ▲ Buy | Grant | 6,180 | $10K | 7/31/2026 |
| Eylward Susan | ▲ Buy | Grant | 2,541 | $4K | 7/31/2026 |
| Tardugno Michael H | ▲ Buy | Grant | 6,358 | $10K | 7/31/2026 |
| Faller Douglas Vincent | ▲ Buy | Grant | 3,649 | $6K | 7/31/2026 |
| Lindborg Stacy | ▲ Buy | Grant | 5,010 | $8K | 7/31/2026 |
| Eylward Susan | ▼ Sell | Open Market | 2,150 | $4K | 7/20/2026 |
| Tardugno Michael H | ▲ Buy | Grant | 4,603 | $8K | 7/17/2026 |
| Eylward Susan | ▲ Buy | Grant | 2,150 | $4K | 7/17/2026 |
| Faller Douglas Vincent | ▲ Buy | Grant | 3,082 | $6K | 7/17/2026 |
| Lindborg Stacy | ▲ Buy | Grant | 4,907 | $9K | 7/17/2026 |
| Eylward Susan | ▼ Sell | Open Market | 920 | $2K | 7/6/2026 |
| Tardugno Michael H | ▲ Buy | Grant | 4,410 | $8K | 7/2/2026 |
| Eylward Susan | ▲ Buy | Grant | 920 | $2K | 7/2/2026 |
| Faller Douglas Vincent | ▲ Buy | Grant | 1,308 | $2K | 7/2/2026 |
| Lindborg Stacy | ▲ Buy | Grant | 2,534 | $5K | 7/2/2026 |
| Eylward Susan | ▼ Sell | Open Market | 11,800 | $21K | 6/29/2026 |
| Faller Douglas Vincent | ▲ Buy | Grant | 21,896 | $38K | 6/25/2026 |
| Eylward Susan | ▲ Buy | Grant | 14,696 | $25K | 6/25/2026 |
| Tardugno Michael H | ▲ Buy | Grant | 42,519 | $73K | 6/25/2026 |
| Lindborg Stacy | ▲ Buy | Grant | 67,150 | $115K | 6/25/2026 |
| Tardugno Michael H | ▲ Buy | Grant | 4,629 | $8K | 6/18/2026 |
| Lindborg Stacy | ▲ Buy | Grant | 1,803 | $3K | 6/18/2026 |
| Tardugno Michael H | ▲ Buy | Grant | 4,089 | $8K | 6/5/2026 |
| Lindborg Stacy | ▲ Buy | Grant | 1,593 | $3K | 6/5/2026 |
| Tardugno Michael H | ▲ Buy | Grant | 3,484 | $8K | 5/22/2026 |
| Pellizzari Christine A | ▲ Buy | Grant | 5,557 | $12K | 5/22/2026 |
| James E. Dentzer | ▲ Buy | Grant | 11,148 | $25K | 5/22/2026 |
| Braun Donald P | ▲ Buy | Grant | 5,011 | $11K | 5/22/2026 |
| Fritz Frederick J. | ▲ Buy | Grant | 10,330 | $23K | 5/22/2026 |
| Lindborg Stacy | ▲ Buy | Grant | 1,491 | $3K | 5/22/2026 |
| Lindborg Stacy | ▲ Buy | Option Exercise | 1,667 | $0 | 9/6/2025 |
| James E. Dentzer | ▲ Buy | Grant | 3,318 | $31K | 8/4/2025 |
| Pellizzari Christine A | ▲ Buy | Grant | 2,248 | $21K | 8/4/2025 |
| Braun Donald P | ▲ Buy | Grant | 2,040 | $19K | 8/4/2025 |
| Fritz Frederick J. | ▲ Buy | Grant | 3,161 | $29K | 8/4/2025 |
| Braun Donald P | ▲ Buy | Open Market | 25,000 | $29K | 8/20/2024 |
| Lindborg Stacy | ▲ Buy | Open Market | 25,000 | $25K | 8/15/2024 |
| Tardugno Michael H | ▲ Buy | Open Market | 25,000 | $26K | 8/15/2024 |
| Hazard Sebastien | ▲ Buy | Grant | 20,000 | $0 | 12/7/2023 |
| Goff Corinne Le | ▲ Buy | Grant | 53,000 | $0 | 7/18/2022 |
| Tardugno Michael H | ▲ Buy | Open Market | 4,000 | $14K | 4/12/2022 |
| Fritz Frederick J. | ▲ Buy | Open Market | 5,000 | $20K | 4/8/2022 |
| Fritz Frederick J. | ▲ Buy | Open Market | 2,000 | $9K | 3/2/2022 |
| Kardaras Constantine John | ▲ Buy | Grant | 10,000 | $0 | 12/14/2021 |
| Fritz Frederick J. | ▲ Buy | Open Market | 20,000 | $18K | 10/7/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
Imunon Shares Debt Conversion and Ovarian Cancer Data
Imunon Inc. disclosed that it converted $1.2 million of debt into equity. Additionally, the company shared research data for IMNN-001 in frontline ovarian cancer during an R&D day. These updates provide context for the stock's current trading range, which remains well below the average analyst target price.
Imunon Shares Debt Conversion and Ovarian Cancer Data. Imunon Inc. disclosed that it converted $1.2 million of debt into equity. Additionally, the company shared research data for IMNN-001 in frontline ovarian cancer during an R&D day. These updates provide context for the stock's current trading range, which remains well below the average analyst target price.